GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Rangering i aksjer
#3649
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Aksjekurs
$27.44
Markedsverdi
$4.65B
Endring (1 dag)
-0.35%
Endring (1 år)
-12.44%
Land
IN
Handel GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Kategori
Healthcare
P/S-forhold for GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
P/S-forhold per October 2026 TTM: 10.72
Ifølge GlaxoSmithKline Pharmaceuticals Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 10.72. Ved slutten av 2024 hadde selskapet et P/S-forhold på 9.74.
P/S-historikk for GlaxoSmithKline Pharmaceuticals Limited fra 2004 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 10.72 | -15.16% |
| 2025 | 12.64 | 29.73% |
| 2024 | 9.74 | 41.17% |
| 2023 | 6.90 | -19.88% |
| 2022 | 8.61 | 3.26% |
| 2021 | 8.34 | 26.28% |
| 2020 | 6.61 | -6.14% |
| 2019 | 7.04 | 13.41% |
| 2018 | 6.21 | -22.36% |
| 2017 | 7.99 | -31.64% |
| 2016 | 11.69 | 6.32% |
| 2015 | 11.00 | 10.60% |
| 2013 | 9.94 | 43.71% |
| 2012 | 6.92 | -0.12% |
| 2011 | 6.93 | -24.74% |
| 2010 | 9.20 | 28.61% |
| 2009 | 7.16 | 24.35% |
| 2008 | 5.76 | 6.38% |
| 2007 | 5.41 | -12.92% |
| 2006 | 6.21 | -1.99% |
| 2005 | 6.34 | 32.89% |
| 2004 | 4.77 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 14.32 | 33.54% |
US
|
|
| 6.16 | -42.56% |
US
|
|
| 7.78 | -27.45% |
US
|
|
| 5.48 | -48.88% |
US
|
|
| 4.66 | -56.56% |
CH
|
